Is 50 mg of Xyosted (testosterone enanthate) equivalent to 50 mg of testosterone cypionate?

Is 50 mg Xyosted Equivalent to 50 mg Testosterone Cypionate?

No, 50 mg of Xyosted (testosterone enanthate subcutaneous autoinjector) is NOT directly equivalent to 50 mg of testosterone cypionate intramuscular injection, because the route of administration, pharmacokinetics, and FDA-approved delivery systems differ significantly—though both deliver the same milligram dose of testosterone ester.

Key Differences Between the Two Formulations

Route of Administration

• Xyosted is FDA-approved exclusively for subcutaneous (SC) injection using a prefilled autoinjector with a 27-gauge, five-eighths-inch needle 1.
• Testosterone cypionate is traditionally administered intramuscularly (IM) into the gluteal muscle or vastus lateralis (thigh) 2, 3, 4.
• Although off-label SC administration of testosterone cypionate has been studied and shown to be effective, it is not the FDA-approved route for that formulation 5, 6, 7, 8.

Pharmacokinetic Profiles

• Xyosted (SC testosterone enanthate) was specifically engineered to produce lower peak-to-trough testosterone fluctuations compared with traditional IM testosterone esters 9.
• IM testosterone cypionate at 100–200 mg every 2 weeks generates supraphysiologic peaks (days 2–7) and subtherapeutic troughs (days 13–14), whereas weekly SC dosing provides more stable serum testosterone concentrations 3, 6.
• In a direct comparison study, SC testosterone enanthate autoinjector (SCTE-AI) at 100 mg weekly was independently associated with lower post-therapy estradiol (E2) and hematocrit (HCT) levels compared with IM testosterone cypionate 100 mg weekly, despite achieving equivalent total testosterone levels 6.
• Both SC testosterone enanthate and SC testosterone cypionate (when used off-label) deliver comparable total testosterone exposure to IM administration, but with reduced injection-site pain and improved patient preference 5, 7, 9.

Dosing and Titration

• Xyosted is available in three fixed strengths: 50 mg/0.5 mL, 75 mg/0.5 mL, and 100 mg/0.5 mL, all administered weekly 1.
• Testosterone cypionate is typically dosed at 75–100 mg IM weekly or 150–200 mg IM every 2 weeks, with the Endocrine Society recommending weekly dosing for superior hormonal stability 2, 3.
• A 50 mg weekly dose of either formulation is at the lower end of the therapeutic range and may require upward titration to achieve target serum testosterone levels of 400–700 ng/dL 3, 10, 9.

Monitoring and Safety Considerations

Serum Testosterone Monitoring

• For weekly injections of either formulation, obtain serum testosterone mid-interval (approximately day 3–4 after the dose) to reflect average exposure rather than a trough or peak 3, 10.
• Target serum testosterone in the mid-normal range of 400–700 ng/dL; adjust the dose if levels are >700 ng/dL or <350 ng/dL 3, 10.
• Measure testosterone at 3–6 months after initiation or any dose change, then annually once stable 3, 10, 4.

Hematocrit Surveillance

• Check hematocrit at baseline, 3–6 months, and annually thereafter 3, 10, 4.
• Discontinue therapy immediately if hematocrit exceeds 54 %; evaluate for hypoxia or sleep apnea and consider restarting at a reduced dose after normalization 3, 10, 4.
• SC testosterone enanthate (Xyosted) is associated with lower hematocrit elevations compared with IM testosterone cypionate, which may confer a safety advantage 6.

Prostate Monitoring (Men ≥40 Years)

• Obtain baseline PSA and digital rectal exam, repeat PSA at 3–6 months, then annually 3, 10, 4.
• Refer to urology if PSA rises >1.4 ng/mL within 12 months, PSA velocity >0.4 ng/mL per year, or digital rectal exam is abnormal 3, 10.

Clinical Bottom Line

While 50 mg of Xyosted and 50 mg of testosterone cypionate deliver the same milligram dose of testosterone ester, they are not interchangeable due to differences in route (SC vs. IM), pharmacokinetics (lower peak-to-trough ratio with Xyosted), and FDA-approved delivery systems (autoinjector vs. traditional syringe). 1, 6, 9

Xyosted offers the advantages of easier self-administration, reduced injection-site discomfort, and potentially lower estradiol and hematocrit elevations, making it a preferable option for patients who can tolerate weekly SC injections 5, 6, 7, 9.

Testosterone cypionate remains the most cost-effective option (≈$156 annually vs. higher costs for Xyosted) and is appropriate for patients who prefer IM administration or have cost constraints 3.

Both formulations require identical monitoring protocols (testosterone, hematocrit, PSA) and share the same absolute contraindications (prostate cancer, breast cancer, baseline hematocrit >50 %, untreated severe obstructive sleep apnea) 2, 3, 4.